Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease.

2.50
Hdl Handle:
http://hdl.handle.net/2436/29446
Title:
Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease.
Authors:
Reynolds, Gary; Billingham, Lucinda; Gray, Laura; Flavell, Joanne R.; Najafipour, Sohrab; Crocker, John; Nelson, Paul N.; Young, Lawrence S.; Murray, Paul G.
Abstract:
Interleukin 6 (IL-6) is a potent immunomodulatory cytokine that has pathogenic and prognostic significance in a number of disorders. Previous studies in Hodgkin's disease (HD) have demonstrated the association between elevated serum levels of IL-6 and unfavourable prognosis, including advanced stage and the presence of 'B' symptoms and with reduced survival. Although IL-6 expression has been demonstrated in both the malignant Hodgkin/Reed-Sternberg (HRS) cells and in the various non-malignant cells present in HD biopsies, a relationship between expression of IL-6 by the tumour and outcome measures has not been established. The study group comprised of 97 patients with advanced HD who were recruited to two related clinical trials. IL-6 expression was determined on paraffin-wax sections of biopsy material by means of an immunohistochemical assay. Of the 97 patients, 27 (28%) showed staining for IL-6 in HRS cells. IL-6 expression by HRS cells was significantly correlated with a decreased likelihood of achieving a complete response to chemotherapy (P = 0.02) and with an increased prevalence of 'B' symptoms (P = 0.04). IL-6 expression by HRS cells was not associated with Epstein-Barr virus status (P = 0.57). In summary, the results suggest that IL-6 expression by HRS cells may contribute to the presence of 'B' symptoms and to a decreased likelihood to achieve a complete remission in HD patients.
Citation:
British Journal of Haematology, 118 (1): 195-201
Publisher:
Blackwell Synergy
Journal:
British Journal of Haematology
Issue Date:
2002
URI:
http://hdl.handle.net/2436/29446
DOI:
10.1046/j.1365-2141.2002.03575.x
PubMed ID:
12100148
Additional Links:
http://www.ingentaconnect.com/content/bsc/bjh/2002/00000118/00000001/art00027?token=0051107f39412f415d487725737b742b2f423f5142253048296a7c2849266d656cc66329cb2bf6951
Type:
Article
Language:
en
ISSN:
0007-1048
Appears in Collections:
Molecular Immunology Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorReynolds, Gary-
dc.contributor.authorBillingham, Lucinda-
dc.contributor.authorGray, Laura-
dc.contributor.authorFlavell, Joanne R.-
dc.contributor.authorNajafipour, Sohrab-
dc.contributor.authorCrocker, John-
dc.contributor.authorNelson, Paul N.-
dc.contributor.authorYoung, Lawrence S.-
dc.contributor.authorMurray, Paul G.-
dc.date.accessioned2008-06-04T10:26:02Z-
dc.date.available2008-06-04T10:26:02Z-
dc.date.issued2002-
dc.identifier.citationBritish Journal of Haematology, 118 (1): 195-201en
dc.identifier.issn0007-1048-
dc.identifier.pmid12100148-
dc.identifier.doi10.1046/j.1365-2141.2002.03575.x-
dc.identifier.urihttp://hdl.handle.net/2436/29446-
dc.description.abstractInterleukin 6 (IL-6) is a potent immunomodulatory cytokine that has pathogenic and prognostic significance in a number of disorders. Previous studies in Hodgkin's disease (HD) have demonstrated the association between elevated serum levels of IL-6 and unfavourable prognosis, including advanced stage and the presence of 'B' symptoms and with reduced survival. Although IL-6 expression has been demonstrated in both the malignant Hodgkin/Reed-Sternberg (HRS) cells and in the various non-malignant cells present in HD biopsies, a relationship between expression of IL-6 by the tumour and outcome measures has not been established. The study group comprised of 97 patients with advanced HD who were recruited to two related clinical trials. IL-6 expression was determined on paraffin-wax sections of biopsy material by means of an immunohistochemical assay. Of the 97 patients, 27 (28%) showed staining for IL-6 in HRS cells. IL-6 expression by HRS cells was significantly correlated with a decreased likelihood of achieving a complete response to chemotherapy (P = 0.02) and with an increased prevalence of 'B' symptoms (P = 0.04). IL-6 expression by HRS cells was not associated with Epstein-Barr virus status (P = 0.57). In summary, the results suggest that IL-6 expression by HRS cells may contribute to the presence of 'B' symptoms and to a decreased likelihood to achieve a complete remission in HD patients.en
dc.language.isoenen
dc.publisherBlackwell Synergyen
dc.relation.urlhttp://www.ingentaconnect.com/content/bsc/bjh/2002/00000118/00000001/art00027?token=0051107f39412f415d487725737b742b2f423f5142253048296a7c2849266d656cc66329cb2bf6951en
dc.subjectHodgkin's Diseaseen
dc.subjectInterleukin 6en
dc.subjectImmunohistochemistryen
dc.subjectB symptomsen
dc.subjectRemissionen
dc.subject.meshAdulten
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen
dc.subject.meshBiological Markersen
dc.subject.meshDisease-Free Survivalen
dc.subject.meshEpstein-Barr Virus Infectionsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunohistochemistryen
dc.subject.meshInterleukin-6en
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPrognosisen
dc.subject.meshReed-Sternberg Cellsen
dc.subject.meshRegression Analysisen
dc.subject.meshRemission Inductionen
dc.titleInterleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease.en
dc.typeArticleen
dc.identifier.journalBritish Journal of Haematologyen

Related articles on PubMed

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.